- Home
- STK vs MYGN Comparison
STK vs MYGN Comparison
Compare STK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- MYGN
- Stock Information
- Founded
- STK 2009
- MYGN 1991
- Country
- STK United States
- MYGN United States
- Employees
- STK N/A
- MYGN N/A
- Industry
- STK Investment Managers
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STK Finance
- MYGN Health Care
- Exchange
- STK Nasdaq
- MYGN Nasdaq
- Market Cap
- STK 511.3M
- MYGN 423.1M
- IPO Year
- STK N/A
- MYGN 1995
- Fundamental
- Price
- STK $32.65
- MYGN $6.75
- Analyst Decision
- STK
- MYGN Hold
- Analyst Count
- STK 0
- MYGN 13
- Target Price
- STK N/A
- MYGN $13.50
- AVG Volume (30 Days)
- STK 38.2K
- MYGN 1.5M
- Earning Date
- STK 01-01-0001
- MYGN 11-06-2025
- Dividend Yield
- STK 6.60%
- MYGN N/A
- EPS Growth
- STK N/A
- MYGN N/A
- EPS
- STK N/A
- MYGN N/A
- Revenue
- STK N/A
- MYGN $832,900,000.00
- Revenue This Year
- STK N/A
- MYGN $0.17
- Revenue Next Year
- STK N/A
- MYGN $6.19
- P/E Ratio
- STK N/A
- MYGN N/A
- Revenue Growth
- STK N/A
- MYGN 3.83
- 52 Week Low
- STK $24.95
- MYGN $3.76
- 52 Week High
- STK $34.31
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- STK 67.47
- MYGN 66.43
- Support Level
- STK $31.07
- MYGN $5.78
- Resistance Level
- STK $32.00
- MYGN $6.99
- Average True Range (ATR)
- STK 0.41
- MYGN 0.35
- MACD
- STK 0.08
- MYGN 0.06
- Stochastic Oscillator
- STK 95.82
- MYGN 83.24
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.